• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps Over 100 Points; Chicago Fed National Activity Rises In March

    4/22/24 9:41:41 AM ET
    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Blank Checks
    Finance
    Get the next $HEPA alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday.

    Following the market opening Monday, the Dow traded up 0.31% to 38,104.99 while the NASDAQ rose 0.62% to 15,376.02. The S&P 500 also rose, gaining, 0.40% to 4,987.10.

    Check This Out: Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday

    Leading and Lagging Sectors

    Information technology shares climbed by 0.8% on Monday.

    In trading on Monday, energy shares fell by 0.4%.

    Top Headline

    The Chicago Fed National Activity Index increased to +0.15 in March versus a revised reading of +0.09 in the previous month, topping market estimates of +0.09.

    Equities Trading UP
                           

    • Moolec Science SA (NASDAQ:MLEC) shares shot up 118% to $3.0150 after the company announced that it received USDA approval for plant-grown animal proteins.
    • Shares of NewGenIvf Group Limited (NASDAQ:NIVF) got a boost, surging 76% to $1.30 after the company signed a non-binding term sheet for a potential reverse merger with European Wellness Investment Holdings.
    • SuperCom Ltd. (NASDAQ:SPCB) shares were also up, gaining 36% to $0.2987 after the company reported better-than-expected fourth-quarter results.

    Equities Trading DOWN

    • Vaxxinity, Inc. (NASDAQ:VAXX) shares dropped 58% to $0.2001 after the company announced its intention to voluntarily delist and deregister its Class A common stock.
    • Shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) were down 37% to $1.33 after the company announced that it began wind-down activities in its Phase 2b “ASCEND-NASH Trial.
    • Connexa Sports Technologies Inc. (NASDAQ:YYAI) was down, falling 57% to $0.8945.

    Also Check This Out: This Analyst With 85% Accuracy Rate Sees More Than 37% Upside In AMD – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Commodities

    In commodity news, oil traded down 0.1% to $83.07 while gold traded down 2.4% at $2,356.80.

    Silver traded down 4.6% to $27.525 on Monday, while copper rose 0.2% to $4.5055.

    Euro zone

    European shares were mostly higher today. The eurozone's STOXX 600 rose 0.4%, London's FTSE 100 rose 1.6% while Spain's IBEX 35 Index climbed 1% The German DAX gained 0.5% French CAC 40 rose 0.2% while Italy's FTSE MIB Index fell 1%.

    Eurozone's government deficit to GDP ratio fell to 3.6% in 2023 compared to a revised 3.7% in the prior year.

    Asia Pacific Markets

    Asian markets closed mostly higher on Monday, with Japan's Nikkei 225 gaining 1%, Hong Kong's Hang Seng Index gaining 1.77%, China's Shanghai Composite falling 0.67% and India's S&P BSE Sensex gaining 0.77%.

    The People’s Bank of China maintained its key lending rates at the April fixing.

    Economics

    The Chicago Fed National Activity Index increased to +0.15 in March versus a revised reading of +0.09 in the previous month, topping market estimates of +0.09.

    Now Read This: Progressive, Q2 Holdings And 2 Other Stocks Insiders Are Selling

    Get the next $HEPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HEPA
    $MLEC
    $SPCB
    $VAXX

    CompanyDatePrice TargetRatingAnalyst
    Moolec Science SA
    $MLEC
    9/27/2023$5.00Buy
    ROTH MKM
    Vaxxinity Inc.
    $VAXX
    9/8/2023$7.00Outperform
    Robert W. Baird
    Vaxxinity Inc.
    $VAXX
    4/27/2022In-line
    Evercore ISI
    Hepion Pharmaceuticals Inc.
    $HEPA
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    Vaxxinity Inc.
    $VAXX
    12/29/2021$18.00Buy
    Jefferies
    Vaxxinity Inc.
    $VAXX
    12/7/2021$18.00Buy
    Jefferies
    Vaxxinity Inc.
    $VAXX
    12/6/2021$21.00Buy
    B of A Securities
    More analyst ratings

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SuperCom Secures Louisiana Electronic Monitoring Contract, Expands U.S. Presence to 16th New State

    Marks 17th New Service Provider Partnership Since Mid-2024 and Continues Track Record of Incumbent Displacement TEL AVIV, Israel, Feb. 12, 2026 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today announced a new electronic monitoring (EM) service provider contract in Louisiana. The agreement marks SuperCom's entry into its 16th new U.S. state and its 17th new service provider partnership since mid-2024, further expanding SuperCom's recurring revenue base and U.S. footprint. The Louisiana-based provider has operated electronic monitoring programs across the state for over a decade, managing supervision se

    2/12/26 9:00:00 AM ET
    $SPCB
    Semiconductors
    Technology

    SuperCom Secures Third Electronic Monitoring Project in Wisconsin

    5th new project launch from the start of the new year highlights rapid follow-on expansion through established regional partnerships TEL AVIV, Israel, Feb. 2, 2026 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, today announced the expansion of its electronic monitoring footprint into an additional county in Wisconsin. This latest win marks SuperCom's third project in the state, underscoring the company's ability to scale rapidly following initial deployments. The new project is being launched through SuperCom's Midwest regional service provider partnership established earlier in 2025. Since entering Wiscon

    2/2/26 9:00:00 AM ET
    $SPCB
    Semiconductors
    Technology

    SuperCom Wins Third Electronic Monitoring Contract in North Carolina

    Follow-on deployment in the state builds on initial PureOne rollout announced in December TEL AVIV, Israel, Jan. 22, 2026 /PRNewswire/ -- SuperCom (NASDAQ:SPCB), a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, today announced its third electronic monitoring (EM) contract in North Carolina. The new agreement builds on SuperCom's recent momentum in the state, following its initial PureOne rollout with a local service provider announced in December 2025 and the statewide procurement vehicle awarded earlier in 2025 by the North Carolina Sheriff's Association, reinforcing continued adoption of the Company's technology by service providers launching new

    1/22/26 9:15:00 AM ET
    $SPCB
    Semiconductors
    Technology

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ray Sumita

    4 - Vaxxinity, Inc. (0001851657) (Issuer)

    4/29/24 4:15:15 PM ET
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Purcell Michael J.

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/7/24 4:15:14 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Purcell Michael J.

    3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    3/6/24 4:30:41 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    SEC Filings

    View All

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    1/30/26 4:41:07 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    1/23/26 6:30:57 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    1/22/26 9:25:48 AM ET
    $MLEC
    Blank Checks
    Finance

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wijngaard Peter bought $15,350 worth of shares (5,000 units at $3.07), increasing direct ownership by 111% to 9,501 units (SEC Form 4)

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    11/28/23 6:55:05 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Wijngaard Peter bought $16,841 worth of shares (3,000 units at $5.61), increasing direct ownership by 200% to 4,501 units

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    9/20/23 11:27:22 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Foster Robert T bought $8,960 worth of shares (1,600 units at $5.60), increasing direct ownership by 3% to 50,470 units

    4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)

    9/19/23 9:01:30 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Moolec Science with a new price target

    ROTH MKM initiated coverage of Moolec Science with a rating of Buy and set a new price target of $5.00

    9/27/23 7:44:02 AM ET
    $MLEC
    Blank Checks
    Finance

    Robert W. Baird initiated coverage on Vaxxinity with a new price target

    Robert W. Baird initiated coverage of Vaxxinity with a rating of Outperform and set a new price target of $7.00

    9/8/23 7:38:37 AM ET
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on Vaxxinity

    Evercore ISI initiated coverage of Vaxxinity with a rating of In-line

    4/27/22 9:03:26 AM ET
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Leadership Updates

    Live Leadership Updates

    View All

    Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

    EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company's Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified p

    3/6/24 8:30:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

    Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity's leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity's board of directors. Peter will oversee the overall scientific direction of Vaxxinity's platform and programs, and lead the development efforts at Vaxxinity. "Get ready for the next wave of innovative drug science at V

    7/27/23 4:30:36 PM ET
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theralase(R) Announces Appointment of New Independent Director

    TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one o

    6/6/23 7:00:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Financials

    Live finance-specific insights

    View All

    SuperCom Reports Record Net Income of $6 Million and Non-GAAP EPS of $2.17 for the First Nine Months of 2025

    Q3: Non-GAAP Net Income $1.9 Million; EBITDA Margin of 34.6%; EBITDA of $2.2 Million; Non-GAAP EPS $0.39 9 Months: Non-GAAP Net Margin of 45.7%; Non-GAAP Net Income $9.3 Million TEL AVIV, Israel, Nov. 13, 2025 /PRNewswire/ -- SuperCom (NASDAQ:SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today reported results for the three and nine months ended September 30, 2025. First Nine Months Ended September 30, 2025, Financial Highlights (Compared to First Nine months of 2024) Revenue decreased slightly to $20.4 million from $21.3 million. Gross profit increased to $12.5 million from $10.7 million.Gross margin expanded to 61.0% from 50.1%.Operat

    11/13/25 9:15:00 AM ET
    $SPCB
    Semiconductors
    Technology

    SuperCom to Report Third Quarter 2025 Financial Results on November 13, 2025

    TEL AVIV, Israel, Nov. 3, 2025 /PRNewswire/ -- SuperCom (NASDAQ:SPCB), a global provider of secured solutions for the e-Government, IoT and Cybersecurity sectors, will hold a conference call on Thursday, November 13, 2025, at 10 a.m. Eastern time (7 a.m. Pacific Time / 5 p.m. IL time) to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. SuperCom management will host the conference call, followed by a question-and-answer period. Conference Call Dial-In Information: Date: Thursday, November 13, 2025Time: 10 a.m. Eastern time (7 a.m. Pacific time)U.S. toll-free: 888-506-0062Israel toll-free: 1-80

    11/3/25 8:30:00 AM ET
    $SPCB
    Semiconductors
    Technology

    SuperCom Reports Record Net Income of $5.3 Million and Non-GAAP EPS of $1.84 for First Half 2025

    Q2: Revenue of $7.14 Million; Net Income of $1.1 Million; non-GAAP EPS of $0.49 ; EBITDA of $2.5 Million H1: Revenue of $14.2 Million; Gross Margin of 61.2%; Non-GAAP Net Income of $7.4 Million TEL AVIV, Israel, Aug. 14, 2025 /PRNewswire/ -- SuperCom (NASDAQ:SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today reported results for the second quarter, ended June 30, 2025. First Half Ended June 30, 2025, Financial Highlights (Compared to the First Half of 2024) Revenue was $14.2 million, compared to $14.4 million.Gross profit increased by 15.2% to $8.7 million from $7.5 million.Gross margin expanded to 61.2% from 52.3%.Operating income mor

    8/14/25 9:25:00 AM ET
    $SPCB
    Semiconductors
    Technology

    $HEPA
    $MLEC
    $SPCB
    $VAXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    11/14/24 4:07:59 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Moolec Science SA

    SC 13D - Moolec Science SA (0001937737) (Subject)

    4/17/24 5:14:28 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form SC 13G filed by SuperCom Ltd.

    SC 13G - SuperCom Ltd (0001291855) (Subject)

    4/17/24 11:09:45 AM ET
    $SPCB
    Semiconductors
    Technology